[Table_Page]跟 踪研究|制药、生物科技与生命科学 证券研究报告 [【Table_T广itle] 发 医 药 & 海 外 】 和 黄 医 药 [公Tab司le_I评nves级t] 买入 当前价格 34.45港元 （00013.HK） 合理价值 40.73港元 前次评级 买入 ESLIM-01 研究结果发布，持久应答率亮眼 报告日期 2024-05-16 [ 核Tabl 心e_Su 观mm 点ary] ： [相Tab对le_P市icQ场uote表] 现 ⚫ 事件：和黄医药于2024年EHA大会上发布了索乐匹尼布治疗原发性 60% 42% 血小板减少症（ITP）的III期临床（ESLIM-01）数据。根据和黄医药 24% 发布的摘要（S316）信息，该研究为一项随机、双盲、安慰剂对照的 6% III期临床研究，研究地点为中国，注册号为NCT05029635。 -12%05/23 07/23 09/23 11/23 01/24 03/24 05/24 -30% ⚫ 持续应答率表现亮眼，安全性有效性俱佳。根据摘要信息显示，该研究 和黄医药 恒生指数 共入组188名患者，按照2：1的比例随机分配至索乐匹尼布和 ...

Investment Rating - The report maintains a "Buy" rating for the company [3]. Core Insights - The sales of the drug "Yingkuaitini" exceeded expectations, with approximately $67 million in sales in the U.S. as of March 31, 2024, and an expected annual growth rate of over 100% for the fiscal year 2024 [1][2]. - The company is optimistic about the overseas market expansion of "Yingkuaitini" as approvals in Europe and Japan are anticipated [1]. - The drug "Saiwo" is expected to submit its NDA in the U.S. by the end of 2024, marking a significant milestone for the company's innovative pipeline [2]. Financial Summary - The company reported revenues of $426 million in 2022, which increased to $838 million in 2023, with a projected revenue of $704 million for 2024, reflecting a 16% decrease [7]. - Gross profit rose from $115 million in 2022 to $454 million in 2023, with a forecasted gross profit of $377 million for 2024 [7]. - The net profit improved from a loss of $361 million in 2022 to a profit of $101 million in 2023, with an expected loss of $30 million in 2024 [7].

— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib and anti-PD-1 activity with Hengrui's camrelizumab, promoting the immune response against tumor cells — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phase II/III tr ...

Investment Rating - The investment rating for the company is "Buy (Maintain)" [2] Core Views - The report highlights that the sales of Fruzaqla (fruquintinib) in the U.S. exceeded expectations, with sales reaching approximately 65 million USD by March 31, 2024, following its approval in November 2023 [4][7] - The company has a strong pipeline with multiple upcoming approvals and significant unmet medical needs in the oncology sector, particularly for colorectal cancer [4][8] - The report projects revenue growth for the company, with expected sales of 709 million, 912 million, and 1.131 billion USD for the years 2024 to 2026, respectively [5][10] Summary by Sections Company Events - Takeda Pharmaceuticals reported that Fruzaqla's sales in the U.S. reached 101 billion JPY (approximately 65 million USD) by March 31, 2024, with a strong sales performance in Q1 2024 [4] - The company entered into a licensing agreement with Takeda for Fruzaqla's overseas rights, with potential payments totaling up to 1.13 billion USD [4] Market Performance - The report notes that colorectal cancer is a significant global health issue, with over 935,000 deaths in 2020, indicating a large market opportunity for Fruzaqla [4][8] - The company is expanding its indications in China, with multiple applications for new indications under review [4][9] Financial Projections - The report revises the sales expectations for Fruzaqla, forecasting revenues of 709 million, 912 million, and 1.131 billion USD for 2024, 2025, and 2026, respectively, with growth rates of -15%, 29%, and 24% [5][10] - The company is expected to achieve a gross margin of approximately 54% in the coming years [10]

Core Viewpoint - HUTCHMED (China) Limited has appointed Dr. Renu Bhatia as an Independent Non-executive Director, effective May 13, 2024, to enhance the Board's expertise in healthcare and finance sectors [1][2][3]. Group 1: Appointment Details - Dr. Bhatia has over 25 years of experience in healthcare, finance, fintech, and regulatory sectors, and is expected to provide valuable insights to the Board [1][2]. - The initial term of Dr. Bhatia's appointment will end at the next annual general meeting, with a director's fee of US$76,000 and US$8,000 for her role in the Technical Committee [4]. - Dr. Bhatia holds 16,000 ordinary shares in HUTCHMED, representing approximately 0.002% of its issued share capital [5]. Group 2: Background and Experience - Dr. Bhatia is the chairman and co-founder of Opharmic Technology (HK) Ltd, focusing on ultrasound technology for drug delivery, and co-founder of Asia Fintech Angels [2][3]. - She has held significant positions in public service and has a strong background in finance, having started her career at Goldman Sachs and HSBC Asset Management [3]. - Dr. Bhatia holds a Doctor of Medicine from the University of London, an MBA from Yale University, and a Postgraduate Diploma in Therapeutics and Medicine from The University of Hong Kong [3]. Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [6]. - The company employs approximately 5,000 personnel, with a core team of about 1,800 in oncology/immunology [6].

Investors might want to bet on HUTCHMED (HCM) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a chang ...

Shares of HUTCHMED (HCM) have gained 12.8% over the past four weeks to close the last trading session at $18.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26.12 indicates a potential upside of 38.1%.The average comprises five short-term price targets ranging from a low of $17 to a high of $45, with a standard deviation of $11.60. While the lowest estimate indicates a decl ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The approval of Furmonertinib in the US is expected to drive sales growth, with positive trends observed in the US market. The drug is anticipated to receive approvals in Europe and Japan within the year, indicating a strong potential for overseas market expansion [3][4]. - The company is expected to submit a New Drug Application (NDA) for Savolitinib in the US by the end of the year, with a promising pipeline of innovative drugs entering the market [3][4]. Summary by Sections Sales Performance - Furmonertinib's sales in US medical institutions have shown a consistent month-on-month increase since its launch, achieving sales of $1.44 million, $5.18 million, $10.31 million, $13.30 million, and $15.33 million from November 2023 to March 2024, with a peak sales forecast exceeding $500 million [4]. Drug Approvals - Furmonertinib received a positive opinion from the European Medicines Agency (EMA) for treating metastatic colorectal cancer and is expected to be approved soon. Additionally, an NDA was submitted in Japan in September 2023, with expectations for approval in 2024 [4]. Pipeline Developments - The company is advancing its pipeline with Furmonertinib's combination therapy for endometrial cancer expected to present data at the 2024 ASCO conference. The NDA for this combination therapy was accepted for priority review [4]. - Savolitinib has shown promising results in treating first-line MET14 skipping NSCLC, with an overall response rate (ORR) of 62.1% and a disease control rate (DCR) of 92.0%. The NDA for this indication is expected to be submitted in the US by the end of 2024 [4]. Financial Projections - The company reported revenues of $426 million in 2022, with a significant increase to $838 million in 2023, reflecting a growth rate of 97%. Projections for 2024 indicate a revenue decrease of 16%, followed by a recovery in subsequent years [9].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [4][7]. Core Insights - The company is positioned as a leading innovative pharmaceutical enterprise focusing on small molecule drugs, with a strong global sales momentum and a robust pipeline of innovative drugs [3][9]. - The company has 13 innovative drugs in clinical trials, with three already approved in China and one in the United States, indicating a solid foundation for future growth [3][22]. - The financial outlook for 2024 is positive, with projected revenues from oncology and immunology business expected to be between $300 million and $400 million, supported by existing product sales and licensing fees [4][16]. Summary by Sections Globalization and Development - Established in 2000, the company has successfully expanded its market presence internationally, with a strong focus on oncology and immunology [13][16]. - The company has a stable management team with extensive industry experience, contributing to its attractive development prospects [15][16]. Innovative Pipeline - The company has a diverse pipeline with 13 drugs in clinical stages, focusing on small molecule kinase inhibitors targeting various pathways [22]. - Key products include Fruquintinib, which is expected to see significant sales growth in both domestic and international markets, particularly with upcoming approvals for gastric cancer [23][28]. - The company is also advancing its other drugs, such as Surufatinib and Syk inhibitor HMPL-523, which are expected to contribute to future revenue streams [32][34]. Financial Projections and Valuation - Revenue projections for 2024-2026 are estimated at $663 million, $837 million, and $1.065 billion, respectively, reflecting strong growth potential [4][7]. - The company's estimated equity value is approximately 35 billion RMB, equivalent to 38.1 billion HKD, based on a DCF analysis with a perpetual growth rate of 2% [4][7].

Core Viewpoint - Fruquintinib has received a positive opinion from the CHMP for the treatment of previously treated metastatic colorectal cancer in the EU, potentially making it the first novel targeted therapy for this indication in over a decade [1][2][3] Company Overview - HUTCHMED, in partnership with Takeda, is advancing the development and commercialization of fruquintinib, which has shown significant survival benefits in patients with metastatic colorectal cancer [3][10] - Takeda holds the exclusive worldwide license to develop and market fruquintinib outside of mainland China, Hong Kong, and Macau [2][8] Clinical Trial Insights - The positive CHMP opinion is based on the results from the FRESCO-2 Phase III clinical trial, which demonstrated statistically significant improvements in overall survival and progression-free survival for patients treated with fruquintinib [5][6][8] - FRESCO-2 trial included patients from multiple regions, including the U.S., Europe, Japan, and Australia, and met all primary and key secondary endpoints [5][6] Market Context - Colorectal cancer (CRC) is a significant health issue, being the third most prevalent cancer globally, with over 935,000 deaths in 2020 [4] - In Europe, CRC was the second most common cancer in 2020, with approximately 520,000 new cases and 245,000 deaths [4] Product Information - Fruquintinib is a selective oral inhibitor of VEGFR-1, -2, and -3, designed to inhibit tumor angiogenesis with a manageable safety profile [7][8] - The drug has been approved in the U.S. under the brand name FRUZAQLA, based on data from two large Phase III trials involving a total of 734 patients [8][9]